Description

A study by StrategyHelix indicates that the global transplantation and alternatives market is expected to increase by US$ 53.6 billion from 2022 to 2028, garnering a CAGR of 7.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for transplantation and alternatives. The global transplantation and alternatives market is segmented on the basis of product, and region. Based on product, the global transplantation and alternatives market is categorized into alternatives, immunosuppressants, solid organ preservation solutions, tissue products, tissue typing. The alternatives segment captured the largest share of the market in 2021. In terms of geography, the global transplantation and alternatives market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). North America held the largest share of the global transplantation and alternatives market in 2021 and is anticipated to hold its share during the forecast period.

The alternatives market is further segmented into orthopedic alternatives, ventricular assist devices (VADs), and others. According to the research, the orthopedic alternatives segment had the largest share in the global transplantation and alternatives market. Furthermore, the immunosuppressants market has been categorized into anti-proliferative agents, calcineurin inhibitors, m-TOR inhibitors, polyclonal antibodies, and T-cell costimulation blocker. StrategyHelix research indicates that the calcineurin inhibitors segment occupied the largest share of this market in 2021 and is expected to draw the highest demand in coming years. The tissue products market is further divided into heart valves, cornea, orthobiologics, peripheral blood stem cells, skin grafts, soft tissue, and vascular grafts. Globally, the peripheral blood stem cells segment made up the largest share of the transplantation and alternatives market.

As of 2021, the major players in the global transplantation and alternatives market were Amgen Inc., Bayer AG, Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc. Competitive landscape gives a description of the competitive nature of the global transplantation and alternatives market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the transplantation and alternatives market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: alternatives, immunosuppressants, solid organ preservation solutions, tissue products, tissue typing
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: Amgen Inc., Bayer AG, Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc.

Key Benefits for Stakeholders

– Get a comprehensive picture of the global transplantation and alternatives market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Transplantation and alternatives market overview
Part 3. Market breakdown by product
– Alternatives
– Immunosuppressants
– Solid organ preservation solutions
– Tissue products
– Tissue typing
Part 4. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 5. Key companies
– Amgen Inc.
– Bayer AG
– Bristol-Myers Squibb Company (BMS)
– F. Hoffmann-La Roche AG
– Novartis AG
– Pfizer Inc.
About StrategyHelix
Disclaimer